Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

24.3K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
24.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding the phenotypic spectrum of SOD1‑related ALS: upper motor neuron predominance in a p.D91A case.

Neurodegenerative disease management·2026
Same author

Genetic Prognostic Factors in Multiple Sclerosis: Key Discoveries and Unmet Needs.

International journal of molecular sciences·2026
Same author

Mitochondrial Dysfunction: The Cellular Bridge from Emotional Stress to Disease Onset: A Narrative Review.

Biomolecules·2026
Same author

The Epidemiology of Primary Lateral Sclerosis: Results from a Population-Based Cohort.

Annals of neurology·2025
Same author

Profiling cognition and brain metabolism in amyotrophic lateral sclerosis and frontotemporal dementia.

Brain : a journal of neurology·2025
Same author

Amyotrophic Lateral Sclerosis Prevalence Projection in 2040: A Less Rare Disease.

Annals of clinical and translational neurology·2025

Related Experiment Video

Updated: Jul 28, 2025

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development
09:37

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development

Published on: March 5, 2017

13.2K

iPSC-based research in ALS precision medicine.

Letizia Mazzini1, Fabiola De Marchi1

  • 1ALS Centre, Neurology Unit, Department of Translational Medicine, Maggiore della Carità Hospital, University of Piemonte Orientale, Novara, Italy.

Cell Stem Cell
|June 2, 2023
PubMed
Summary

Researchers used patient-derived stem cells to test a drug for amyotrophic lateral sclerosis (ALS). This approach helps identify which patients may respond to ropinirole treatment, addressing a key challenge in ALS clinical trials.

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

862
Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
07:03

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Published on: December 1, 2023

959

Related Experiment Videos

Last Updated: Jul 28, 2025

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development
09:37

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development

Published on: March 5, 2017

13.2K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

862
Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
07:03

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Published on: December 1, 2023

959

Area of Science:

  • Neuroscience
  • Stem Cell Biology
  • Drug Development

Background:

  • Clinical trials for amyotrophic lateral sclerosis (ALS) face significant hurdles due to the absence of reliable pre-clinical models and biomarkers for disease onset and progression.
  • Developing effective treatments for ALS is hampered by the lack of predictive models to assess therapeutic efficacy and identify patient subgroups.

Purpose of the Study:

  • To investigate the therapeutic mechanisms of ropinirole in amyotrophic lateral sclerosis (ALS) using patient-derived induced pluripotent stem cells (iPSCs).
  • To identify potential treatment responders for ropinirole within an ALS patient cohort by analyzing cellular responses in iPSC-derived motor neurons.

Main Methods:

  • Generation of induced pluripotent stem cells (iPSCs) from patients diagnosed with amyotrophic lateral sclerosis (ALS).
  • Differentiation of iPSCs into motor neurons to create patient-specific pre-clinical models.
  • Treatment of iPSC-derived motor neurons with ropinirole to evaluate therapeutic effects and identify biomarkers of response.

Main Results:

  • The study successfully utilized iPSC-derived motor neurons as a model to explore ropinirole's therapeutic potential in ALS.
  • Specific cellular responses were identified, enabling the potential discrimination between treatment responders and non-responders in a clinical trial setting.
  • This methodology provides a foundation for personalized medicine approaches in ALS treatment.

Conclusions:

  • Induced pluripotent stem cell (iPSC)-derived motor neurons offer a valuable platform for studying ALS pathogenesis and testing therapeutic interventions like ropinirole.
  • The identification of treatment responders is crucial for optimizing clinical trial design and improving patient outcomes in ALS.
  • This research highlights the potential of patient-specific stem cell models to advance drug discovery and development for neurodegenerative diseases.